Physician profile
Mohammad Sabbagh
NPI 1568860922
$845.70
in general payments reported to CMS, 2019-2025
14 companies · $39.62 in 2025
The $39.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.87 · 2021: $19.90 · 2022: $362 · 2023: $345 · 2024: $43.42 · 2025: $39.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $493.37 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $67.46 | 2022-2025 | |
| Inspire Medical Systems, INC. | $56.03 | 2023 | Inspire |
| Neurocrine Biosciences, INC. | $48.40 | 2022 | |
| Menarini Silicon Biosystems, INC. | $29.37 | 2023 | Cellsearch |
| Medtronic, INC. | $23.39 | 2023 | Interstim |
| Abbvie INC. | $22.10 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.14 | 2022 | |
| Celgene Corporation | $17.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.70 | 2022 | |
| Spr Therapeutics, INC | $14.15 | 2021-2022 | |
| Zyla Life Sciences, INC. | $13.77 | 2020 | |
| Pfizer INC. | $13.21 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Sabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.